A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Grants and Contracts Details

StatusFinished
Effective start/end date8/31/21 → 4/24/23

Funding

  • IQVIA RDS Incorporated: $26,424.00